Introduction
We have previously described the p140Cap/SNIP adaptor protein as a molecule that directly associates with Src and Csk kinases, and interferes with integrin/ growth factor-dependent Src kinase activity, thus affecting tumour properties in cancer cells (Di Stefano et al., 2007) . The modular structure of p140Cap is characterized by a tyrosine-rich region and two prolinerich regions (Chin et al., 2000; Di Stefano et al., 2004) , which enable binding to effector molecules, such as Csk and Src, respectively (Di Stefano et al., 2007) .
p140Cap is a major regulator of integrin signalling. Mechanistically, on cell-matrix adhesion, p140Cap binds to and activates Csk kinase, phosphorylating Src on the inhibitory tyrosine 527, leading to its inactivation. As a consequence, Src binding to Focal Adhesion Kinase (FAK) is impaired, phosphorylation of the adaptor protein p130Cas is decreased, and Rac GTPase is inactivated. Conversely when p140Cap is knocked down by RNAi, levels of active Src and Rac are strongly increased (Di Stefano et al., 2007) . Elevated expression of p140Cap results in decreased cell spreading, motility, invasion and defects in anchorage-independent growth as well as in vivo tumour growth (Di Stefano et al., 2007) , indicating that p140Cap behaves as a tumour suppressor protein.
In human tumours, perturbation of the complex interplay among the cell-cell, cell matrix and growth factor receptors, resulting in increased proliferation and cell invasion, leads to disruption of the architectural integrity of a tissue, and dissemination of cancer cells into the body (Giancotti and Tarone, 2003; Cavallaro and Christofori, 2004; Guo and Giancotti, 2004; Berx et al., 2007) . The cell-cell adhesion receptor E-cadherin interacts with the epidermal growth factor receptor (EGFR) through a largely unknown mechanism blocking the proliferation programme (Takahashi and Suzuki, 1996; Qian et al., 2004; Perrais et al., 2007) and is frequently downregulated or lost in epithelial tumours (Berx and Van Roy, 2001; Reynolds and Carnahan, 2004; Peinado et al., 2007) . In contrast, expression or activation of EGFR is enhanced in human tumours, leading to uncontrolled cell growth (Schlessinger, 2000; Nicholson et al., 2001; Arteaga, 2002; Normanno et al., 2006) . Working downstream of EGFR, the Ras GTPase mediates cell-cycle regulation through the extracellular signal-regulated kinase (ERK) cascade (Coleman et al., 2004; Schubbert et al., 2007) . This pathway is commonly hyperactive in human cancer.
In this work, we show that p140Cap regulates cell scatter and proliferation in cancer cells through dual control of Src and Ras activities. We present novel insights into a critical role for p140Cap in E-cadherin stabilization at the cell membrane, contact-dependent inhibition of EGFR activity and inactivation of the RasErk1/2 pathway in cancer cells. Moreover, we provide evidence that p140Cap expression in human breast tumours inversely correlates with tumour malignancy.
Results
p140Cap regulates in vitro and in vivo tumour cell proliferation p140Cap is a potent modulator of in vitro and in vivo breast cancer cell proliferation (Di Stefano et al., 2007) .
Two populations of stable overexpressing (p140-oe) and silenced (p140-si) MCF7 cells, generated as previously described (Di Stefano et al., 2007) (Figure 1a , left panel), were plated in equal numbers and counted every two days within 10 days of cell culture. p140Cap overexpressing cells exhibit a dramatic decrease in cell proliferation compared with control cells (Figure 1a , right panel). Accordingly, silenced p140-si cells proliferate at an increased rate (Figure 1b, left panel) . To test the relevance of p140Cap knockdown in in vivo xenograft, MCF7 control and silenced p140-si cells were injected into the mammary fat pad of SCID mice in the absence of oestrogen pellets. Supplement of oestrogen is an essential requirement for MCF7 cells to grow in vivo Figure 1 p140Cap regulates cell proliferation and EGF-dependent signalling. (a) Left panel: extracts from MCF7 Ctr, overexpressing (p140-oe) and silenced for p140Cap (p140-si) cells, were run on 6% SDS-PAGE to analyse p140Cap expression by western blot with p140Cap-specific polyclonal antibodies. The same blot was reprobed with antibodies to Src kinase. Right panel: 10 4 MCF7 Ctr and p140-oe cells were grown in the presence of 10% FCS for 10 days. Every two days, cells were detached and counted. The mean number of cells from three separate experiments is reported on the y-axis (*Po0.05). (b) Left panel: MCF7 Ctr-si and p140-si proliferation was analysed as above for 10 days. The mean number of cells from three separate experiments is reported on the y-axis. Right panel: 10 7 MCF7 Ctr-si and p140-si cells were injected into the mammary fat pad of SCID mice. Tumour volume was measured every week within 70 days and reported on the y-axis (*Po0.05, Student's t-test). (c) Left panel: western blot analysis of p140Cap expression in cell extracts from control (Ctr-si) or p140Cap silenced (p140-si) HT29 cells. Middle panel: 10 4 Ctr-si and p140-si cells were grown in the presence of 10% FCS for 3 days. Cell proliferation was evaluated by MTT assay every day. Absorbance at 570 nm from three separate experiments is reported on the y-axis. Right panel: 1 Â 10 6 Ctr-si and p140-si were injected subcutaneously in SCID mice. Tumour volume was measured twice a week within 22 days and reported on the y-axis (*Po0.05, Student's t-test).
p140Cap controls E-cadherin/EGFR and Ras signalling L Damiano et al (Lacroix and Leclercq, 2004) . Indeed, although MCF7 Ctr did not grow, p140-si cells gave rise to tumours of 160-170 mm 3 mean diameter within seventy days, thus indicating that loss of p140Cap expression confers an oestrogen-independent proliferative advantage to MCF7 breast cancer cells in vivo (Figure 1b, right  panel) .
To assess the role of p140Cap in a different tumour type, p140Cap was silenced in HT-29 colon carcinoma cells. Silenced cells (Figure 1c, left panel) showed an increased rate of proliferation compared with the appropriate controls (Figure 1c , middle panel), as assessed by MTT assay. Finally, after 22 days, injection of silenced cells in SCID mice gave rise to tumours of increased volume compared with control cells (Figure 1c , right panel).
p140Cap regulates EGF-dependent signalling
The EGFR family is overexpressed and activated in breast and colon cancer (Kim and Muller, 1999) . To define the involvement of p140Cap in EGFR signalling, Erk1/2 activation was analysed in extracts of MCF7 cells plated in confluent conditions treated with FCS or EGF for 5 min, the time point of maximal activation of Erk1/2 (data not shown). In response to both FCS and EGF, Erk1/2 phosphorylation was markedly decreased in p140Cap overexpressing cells and increased two-fold in p140-si cells (Figure 2a ). p140-si cells were rescued by transient transfection with mouse p140Cap full-length cDNA to recover protein expression. These cells-induced Erk1/2 activity at a level comparable with control cells (data not shown).
Interestingly, p140Cap overexpressing cells show an 80% decrease in EGFR phosphorylation compared with control cells (Figure 2b ), indicating that p140Cap regulates EGF-dependent EGFR phosphorylation. Moreover, Shc tyrosine phosphorylation and its association with Grb2, as well as Ras activity tested by an in vitro pull-down on (GST)-Raf-Ras binding domain (RBD), were strongly decreased in p140Cap overexpressing cells compared with control cells (Figures 2c and d) . Accordingly, p140-si cells display a four-fold increase in EGFR phosphorylation, a two-fold increase in Shc phosphorylation and association with Grb2 and in Ras activity (Figures 2b-d) . Consistently, when HT-29 p140-si cells were treated with EGF, EGFR phosphorylation was found to increase four-fold (Figure 2e ). Taken together, these results indicate that p140Cap controls early EGFR activation and signalling in both mammary and colon carcinoma tumour cells. p140Cap regulates EGFR signalling through E-cadherin stabilization at the cell membrane p140Cap overexpressing cells grow in culture as compacted epithelial colonies that do not reach confluence (Supplementary Figure S1) , suggesting that p140Cap might enhance cell-contact inhibition of growth. E-cadherin binding between neighbouring cells can prevent EGFR activation and downstream signalling, leading to negative regulation of proliferation (Takahashi and Suzuki, 1996; Gutkind, 2000; Qian et al., 2004; Perrais et al., 2007) . To assess whether p140Cap regulates EGFR signalling through an E-cadherin-dependent mechanism, p140Cap overexpressing MCF7 cells were plated as sparse single cells to avoid formation of any cell-cell interaction (Figure 3a , right panel). Interestingly, on EGF stimulation, p140Cap overexpressing cells in sparse conditions display the same rate of Erk1/2 phosphorylation as do control cells (Figure 3a) . To mimic homophilic engagement mediated by E-cadherin, cells were plated in sparse conditions and treated with EGF in the presence of soluble chimeric Fc-E-cadherin, which binds to cellmembrane E-cadherin and then recapitulates the cellcell adhesion process (Perrais et al., 2007) (Figure 3b , upper panel). Fc-E-cadherin binding causes a decrease in Erk1/2 activation both in p140Cap overexpressing and control cells in a dose-dependent manner ( Figure 3b , lower panel; Supplementary Figure S2A ). Interestingly, p140Cap overexpressing cells show a reduction in ERK activation at the lowest concentration of Fc-E-cadherin compared with control cells, indicating that these cells are more sensitive to homophilic engagement mimicked by Fc-E-cadherin (Supplementary Figure S2A ). Next, control and p140Cap overexpressing cells were treated with EGF in confluent conditions in the absence or presence of the function-blocking anti E-cadherin DECMA antibody (Vestweber and Kemler, 1985) (Figure 3c , upper panel). DECMA-EGF-treated control cells show increased Erk1/2 phosphorylation compared with cells treated only with EGF ( Figure 3c , lower panel), confirming that inhibition of E-cadherin-mediated adhesion increases EGFR signalling. In p140Cap overexpressing cells, blocking of E-cadherin function through DECMA antibody leads to a four-fold increase in Erk phosphorylation. Furthermore, the expression of DeltaC, a C-terminally truncated E-cadherin mutant that retains the ability to undergo homophilic ligation but cannot bind cytoplasmic partners (Sasaki et al., 2000; Qian et al., 2004) , rescues Erk1/2 phosphorylation in p140Cap overexpressing cells (Supplementary Figure S2B) . Therefore, in p140Cap overexpressing cells, blocking E-cadherin homophilic binding or its association with cytoplasmic molecules is sufficient to rescue p140Cap-dependent inhibition of EGFR signalling. Collectively, these findings show that p140Cap influences EGFR signalling in an E-cadherin-dependent manner. Nevertheless, the level of Erk1/2 activation in p140Cap overexpressing cells treated with DECMA is lower than that of control cells, suggesting the presence of an additional, Ecadherin-independent mechanism of Erk inhibition by p140Cap. To investigate this hypothesis, p140Cap has been overexpressed in E-cadherin null SKBR3 breast cancer cells. Consistently, in these cells, p140Cap overexpression leads to a decrease in Erk1/2 phosphorylation (Supplementary Figure S2C) .
Confocal microscopy of MCF7 cells transfected with RFP-p140Cap and ECFP-EGFR constructs, and stained for E-Cadherin, showed that p140Cap localizes with E-cadherin and EGFR at cell-cell contacts in p140Cap controls E-cadherin/EGFR and Ras signalling L Damiano et al confluent cells ( Figure 4A , panels d, h). Furthermore, reciprocal immunoprecipitation of E-Cadherin and EGFR showed that both proteins associate with p140Cap ( Figure 4B ). Interestingly, the amount of EGFR associated with E-Cadherin was increased in p140Cap overexpressing cells and decreased in silenced The amount of Ras protein in cell extracts is shown. (e) Confluent HT29 cells were starved for 12 h and treated with 30 ng/ml EGF for 5 min. Cell extracts were immunoprecipitated with anti-EGFR antibodies and analysed by western blotting with anti-phosphotyrosine antibodies; membranes were stripped and reprobed with anti EGFR antibodies for loading control. In all the panels, results are representative of five independent experiments. The histograms show the ratio between active and total protein levels in arbitrary units (*Po0.05, Student's t-test).
p140Cap controls E-cadherin/EGFR and Ras signalling L Damiano et al cells compared with controls. Reciprocally, more E-cadherin was found to be associated with EGFR in p140Cap overexpressing cells and less in silenced cells. Taken together, these data show that p140Cap associates with E-Cadherin and EGFR, regulating their relative association at the cell membrane. E-cadherin stability and recycling at the cell membrane is crucial for cell-contact growth inhibition (Berx and Van Roy, 2001 ). To examine whether p140Cap is involved in cell-cell contact stability, E-cadherin internalization was monitored on EGTA treatment for 15 and 30 min. In confluent control cells, E-cadherin was internalized after 15 min of EGTA treatment, and cells were completely detached after 30 min ( Figure 5A , panels a-c). Conversely, in p140Cap overexpressing cells, E-cadherin internalization and cell-cell detachment was prevented, even after 30 min of EGTA treatment ( Figure 5A , panels d-f). Interestingly, in p140-si cells, E-Cadherin was mainly localized in the cytoplasm or in weaker and less clearly formed cell-cell junctions ( Figure 5A , panel g), even in the absence of EGTA treatment. Accordingly, silenced cells showed considerable E-cadherin internalization and cell detachment after 15 min of EGTA treatment ( Figure 5A , panels h, i). Moreover, biotinylated E-cadherin was increased in p140Cap overexpressing cells and decreased in silenced cells ( Figure 5B ). Taken together, these data indicate that p140Cap regulates E-cadherin stability at the cell membrane, influencing cell-cell contact. schematic model of the approach used to selectively engage E-cadherin onto homophilic adhesive bonds at the cell surface. Ctr and p140-oe cells were plated as single cells as in a, and treated for 3 h with soluble chimeric Fc-E-cadherin to activate E-cadherin ligation at the cell surface. 30 ng/ml EGF was added in the last 5 min. Lower panel: cells were evaluated for Erk1/2 activation as in a. (c) Upper panel: schematic model of the approach used to selectively disrupt E-cadherin homophilic adhesive bonds at the cell surface. Ctr and p140-oe cells were plated at confluence, serum deprived overnight and treated with EGTA for 30 min. Where indicated, cells were treated with the function-blocking anti E-cadherin DECMA antibody for 30 min or with EGF for 5 min. Lower panel: cells were evaluated for Erk1/2 activation as in a. In all panels, results are representative of three independent experiments. The histograms show the ratio between active and total protein levels in arbitrary units (*Po0.05, Student's t-test).
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The dynamics of E-Cadherin was further characterized by fluorescence recovery after photobleaching (FRAP), with a functional EGFP-E-Cadherin fusion protein (Miranda et al., 2001) , that correctly localizes at the cell membrane ( Figure 5C , upper panels). Signal recovery curves ( Figure 5C , lower panel) show that p140Cap overexpressing cells have a higher amount of the immobile fraction (35%) compared with control cells (20%), confirming that p140Cap stabilizes E-Cadherin molecules at the cell membrane. Representative pictures Figure 4 p140Cap colocalizes with E-cadherin and EGFR at the cell surface. (A) MCF7 control cells were transfected with p140Cap-RFP (panels a, e) and EGFR-ECFP (panels c, g). Cells were fixed and stained for E-Cadherin using an Alexa 647-conjugated secondary antibody (b, f). p140Cap (panels a, e) colocalizes with E-Cadherin (panels b, f) at cell-cell junctions. In addition, p140Cap colocalizes with EGFR (panels c, g) at cell-cell contacts (panels d, h for merge). Arrows indicate the regions of colocalization (bar is 10 mm). (B) MCF7 Ctr, p140-oe, Ctr-si and p140-si cell extracts were immunoprecipitated with mAb to EGFR or E-cadherin, or pre-immune serum (PI) and blotted with antibodies to EGFR, p140Cap and E-cadherin. The ratio of the association between E-Cadherin and EGFR is reported in arbitrary units in the histogram (*Po0.05, Student's t-test).
p140Cap controls E-cadherin/EGFR and Ras signalling L Damiano et al of the EGFP-E-Cadherin FRAP are shown in Figure 5C (see also Supplementary Video 1-2). p140-si cells were not analysed by FRAP because they show weak junctions that are not comparable with those of control and p140-oe cells. Adherens junction dynamics are important for cell scatter. When cells were plated as small colonies of 10-20 cells, and treated with EGF for 12 h, while control cells scattered ( Figure 5D, panels a, b) , p140Cap overexpressing cells were unable to move (c, d). Accordingly, silenced cells, which have already acquired a more fibroblastic phenotype, have not been subjected to scatter assays for their inability to form compact colonies (Supplementary Figure S3) . Similar results were obtained with HT-29 p140Cap overexpressing cells (Supplementary Figure S4) . Therefore, p140Cap regulates cell-cell contact dynamics by increasing the amount of immobilized E-cadherin at the cell surface, thereby regulating the strength of cell-cell adhesion and the ability of cells to scatter.
p140Cap regulates cell scatter and proliferation through dual control of Src and Ras activities p140Cap controls integrin-dependent Src kinase activity (Di Stefano et al., 2007) . In response to EGF, Src kinase activation was impaired in p140Cap overexpressing cells ( Figure 6A , left panels), and increased in a range of 5-fold compared with controls in silenced cells ( Figure 6A , right panels). Moreover, consistent with Src inhibition, phosphorylation of p120Catenin, the well known Src substrate/E-cadherin partner (Alema and Salvatore, 2007; Reynolds, 2007) , was impaired in p140Cap overexpressing cells (data not shown).
Infection of control and p140Cap overexpressing cells with adenoviruses expressing a kinase-defective Csk mutant (Csk-KD)-unable to phosphorylate Src on Tyr527 (Di Stefano et al., 2007) -allowed a strong activation of Src and of EGFR in response to EGF in p140Cap overexpressing cells ( Figure 6B ), indicating that recovering Src rescues EGFR activation.
In addition, cells expressing the Csk mutant were able to scatter in response to EGF ( Figure 6C, panels c, f) . Indeed, by performing FRAP on control and p140Cap overexpressing cells, EGFP-E-Cadherin membrane dynamics were restored when Csk was silenced by siRNA oligos (Figure 6D ), decreasing the immobile fraction of p140Cap overexpressing cells to the level of Ctr cells. Thus, the rescue of Src kinase activity is sufficient to restore E-Cadherin dynamics, indicating that p140Cap stabilizes E-cadherin at the cell membrane and impairs the EGF-dependent scatter ability by inhibiting Src.
Interestingly, Src kinase rescue with kinase-defective Csk was able to recover EGFR phosphorylation in p140Cap overexpressing cells but not to induce Ras activation and Erk1/2 phosphorylation (Figure 7a) . Consistently, Csk silencing, although inducing Src activation, did not increase Erk1/2 phosphorylation ( Figure 7b ) and cell proliferation (Figure 7d ), indicating that rescue of Src activity is not sufficient to restore Ras/Erk1/2 activities and cell growth. Interestingly, expression of a constitutively active Sos (Aronheim et al., 1994; Yamasaki et al., 2003) , a known GEF for Ras, did not rescue Erk1/2 activity (Supplementary Figure S5A) , whereas transient expression of RasV12 restored EGF-dependent Erk1/2 phosphorylation and cell growth in p140Cap overexpressing cells (Figures 7c-d) . Thus, p140Cap controls Ras and downstream pathways leading to cell proliferation by counteracting Ras activation.
Taken together, these data show that p140Cap has dual control on both Src and Ras activities, which regulate cell scatter and Erk1/2 dependent cell proliferation, respectively (Figure 7e ).
p140Cap is lost in aggressive human breast cancers
The expression of the p140Cap protein was analysed in 55 human breast cancer specimens and 7 specimens of normal breast tissue by immunohistochemistry using specific affinity-purified antibody to p140Cap ((Di Stefano et al., 2004) , Supplementary Figure S6 ). In the normal human breast, p140Cap is expressed selectively in luminal cells of alveoli, whereas no staining is detectable in ductal epithelial cells or myoepithelial cells ( Figure 8B , panels a-b). Analysis of breast cancer tissues showed that p140Cap is expressed in 16 of 55 tumours ( Figures 8A and B, panels c-d) . Interestingly, 94.8% of aggressive G3 tumours, 87% of the Node þ , 86.5% of tumours with a mitosis major number of 10/10HPF, and 76% of highly proliferative tumours (revealed by Ki67 staining) lose p140Cap expression. Moreover, none of the EGFR-positive tumours express p140Cap ( Figure 8B , panels e-f), suggesting a mutually exclusive correlation between EGFR and p140Cap expression. Taken together, these data indicate that the most aggressive breast tumours do not express p140Cap, showing an inverse correlation with the state of malignancy.
Discussion
In this work, we show that the p140Cap adaptor protein regulates cancer cell scatter and proliferation by two mechanisms: (i) immobilizing E-cadherin at the cell membrane and affecting early EGFR signalling and (ii) inhibiting Ras downstream to EGFR. These complementary mechanisms lead to a substantial loss of tumour properties in terms of cell motility and growth.
Our previous results and the data presented here show that p140Cap expression regulates the rate of proliferation of breast and colon cancer cells. Forced expression of p140Cap in tumourigenic breast cancer cells strongly inhibits tumour formation in nude mice (Di Stefano et al., 2007) . Consistently, p140Cap silencing in MCF7 or HT-29 carcinoma cells dramatically increases in vivo tumour formation. Strikingly, p140Cap knockdown is sufficient for in vivo growth of MCF7 cells even in the absence of oestrogen pellets, a condition in which control cells are unable to grow. These last findings p140Cap controls E-cadherin/EGFR and Ras signalling L Damiano et al Figure 6 p140Cap-dependent inhibition of Src controls EGFR phosphorylation and E-Cadherin/cell scatter dynamics. (A) Ctr, p140-oe, Ctr-si and p140-si cells were serum deprived overnight and stimulated with 30 ng/ml EGF for 5 min and extracted. Src kinase assay was performed as described in Methods using Enolase as Src substrate. The amount of Src in cell extracts was evaluated by western blotting with specific antibodies. To show that there is no activation of Src in response to EGF in p140-oe cells, we showed a longer exposure, and therefore the amount of Src activity in Ctr cells is higher than in Ctr-si. Results are representative of three independent experiments. The histograms show the ratio between active and total protein levels in arbitrary units (*Po0.05, Student's t-test). also raise the possibility that p140Cap may regulate oestrogen receptor signalling, contributing to breast cancer resistance to hormonal therapies. Thus, these data provide evidence that p140Cap behaves mechanistically as a tumour suppressor molecule in breast and colon cancer cells, with a broad effect on cell proliferation and tumourigenesis. In human tumours, previous analysis only at the level of mRNA (Kennedy et al., 2008) showed a positive correlation with unfavourable prognostic factors. However, as Figure 7 p140Cap controls Erk1/2 phosphorylation and cell proliferation regulating Ras. (a) Ctr and p140-oe cells were infected with GFP or kinase-negative Csk mutant (Csk-KD) recombinant adenoviruses. Cells were serum deprived for 12 h and stimulated with EGF for 5 min. Left panels: active Ras was pulled-down from 0.6 mg of protein extracts by means of agarose-coupled GST-RBD beads, and detected by western blotting with anti Ras mAbs. The amount of Ras protein in cell extracts is shown. The amount of protein extracts is normalized using anti-vinculin antibodies. Right panels: cell extracts were analysed for Erk1/2 activation and for the total amount of Erk and Csk using specific antibodies. (b) Ctr and p140-oe cells were transiently transfected with Csk siRNA oligos ( þ ) or a scramble RNAi as control (À). After 72 h, cells were serum deprived overnight and treated with EGF for 5 min. Cells extracts were analysed for Erk1/2 activation and for the total amount of Erk, Src and Csk using specific antibodies. (c) Ctr and p140-oe cells were transiently transfected with a RasV12 construct. After 24 h, cells were serum deprived overnight and treated with EGF for 5 min. Cell extracts were analysed for Erk1/2 activation and the total amount of Erk, Csk and Ras using specific antibodies. Lower panel: the histogram shows the ratio between active and total protein levels in arbitrary units (*Po0.05, Student's t-test). (d) To analyse cell growth, Ctr and p140-oe cells were left untreated (black bars), transfected with Csk siRNA (grey bars) as in c, or with RasV12 (white bars), as in d. After 72 h, cell proliferation in the presence of serum was evaluated by MTT assay at 570 nm (*Po0.05, Student's t-test).
(e) Schematic model of the dual control exerted by p140Cap on Src and Ras activities. In confluent tumour cells, p140Cap, by inhibiting Src kinase, immobilizes E-cadherin at the cell membrane, leading to impaired EGF-dependent early EGFR signalling. In addition, downstream to EGFR, p140Cap also inhibits Ras, which in turn negatively regulates Erk1/2 activation. As a consequence of this dual mechanism, scatter and proliferation are inhibited.
p140Cap controls E-cadherin/EGFR and Ras signalling L Damiano et al the mRNA levels may not show any significant correlation with protein levels, we performed immunohistochemistry analysis with specific p140Cap purified antibodies. p140Cap is indeed expressed in normal breast tissue, in which it is confined to the luminal cells of alveoli, suggesting that in normal conditions p140Cap might have a role in mammary cell differentiation. p140Cap is not expressed in 70% of tumour specimens; interestingly, these tumours are the most aggressive in terms of grade and number of mitosis, indicating that the absence of p140Cap correlates with the worst cancer properties. The p140Cap gene localizes on human chromosome 17q12. Chromosome 17q12 and flanking regions contain several genes involved in tumour onset and progression such as ERBB2 (17q12), BRCA1 (17q21), RARA (17q21) and STAT3 (17q21). Therefore, Immunostaining of a G1 ductal breast cancer. Two consecutive tissue array sections were stained with p140Cap antibodies and E-cadherin antibodies (panels c, d). Immunostaining of a G3 ductal breast cancer. Two consecutive tissue array sections were stained with p140Cap antibodies and EGFR antibodies (panels e, f).
p140Cap controls E-cadherin/EGFR and Ras signalling L Damiano et al the poor level of expression of p140Cap in breast tumours might be due to the chromosomal rearrangement frequently observed in this region in several types of cancer (Glynn et al., 2010) . Furthermore, in our screening, p140Cap is not detectable in any EGFR-positive tumours, highlighting an inverse correlation between EGFR and p140Cap expression that support a possible role of p140Cap as an antagonist of EGFR in cancer cells. Here we provide evidence that p140Cap specifically interferes with early EGFR signalling in both breast and colon cancer cells. EGFR activation, association and phosphorylation of Grb2 and Shc and Ras/Erk1/2 MAPK activities are profoundly impaired by p140Cap overexpression and enhanced by its silencing. p140Cap regulates EGFR signalling with dual mechanisms, involving both an E-cadherin-dependent inactivation of EGFR and a Ras-dependent inhibition of Erk1/2 activity. The first mechanism is supported by the observation that p140Cap affects EGFR signalling only when E-cadherin is engaged in cell-cell contacts. In fact, in cells expressing high levels of p140Cap, disruption of E-cadherin function by the classical DECMA inhibitory antibody, or by plating cells in sparse conditions restores EGFdependent Erk1/2 phosphorylation. Conversely, in sparse conditions, E-cadherin engagement by a recombinant E-cadherin extracellular domain leads to downregulation of EGFR activation. E-cadherin is known to inhibit EGFR, either by interaction through the extracellular domains, thereby decreasing receptor mobility, ligand affinity and downstream signalling activation, or by a beta catenin-dependent mechanism (Takahashi and Suzuki, 1996; Qian et al., 2004; Perrais et al., 2007) . In the quest of novel regulators of crosstalk between E-cadherin and EGFR at the cell membrane, the data reported here show that p140Cap functionally interacts with E-cadherin and EGFR at the cell membrane, highlighting p140Cap as a new key player in E-cadherin-dependent downregulation of EGFR signalling.
The major mechanism by which p140Cap controls E-cadherin relies on its ability to immobilize E-cadherin at the cell surface, thus resulting in strengthening adhesion between cells and inhibition of cell migratory properties. This mechanism depends on Src kinase activity, as shown by the recovery of E-cadherin mobility at the cell surface through rescue of Src activity by the expression of a kinase-defective Csk mutant, (Di Stefano et al., 2007) or by Csk silencing. In the same conditions, EGFR phosphorylation is restored, as well as the ability to scatter in response to EGF. Thus, p140Cap impairs cancer cell scatter through Src inactivation, which decreases E-cadherin mobility at the cell membrane, thereby affecting EGFR signalling leading to cell motility.
Interestingly, rescue of Src activity and of E-cadherin mobility is not sufficient to recover Ras and Erk1/2 activation and proliferation in cells expressing high levels of p140Cap. Furthermore, in p140Cap overexpressing cells, the maximal extent of Erk1/2 activation, obtained by blocking E-cadherin with DECMA antibodies and using a C-terminally truncated E-cadherin mutant, never reaches the level of control cells, suggesting that p140Cap might regulate the Ras pathway through an additional mechanism. The existence of such a mechanism is also inferred by the observation that p140Cap overexpression also affects Erk1/2 activity in E-cadherin null SKBR3 breast cancer cells. In this context, our data show that p140Cap directly counteracts Ras activation. In fact, although ectopic expression of constitutively active Sos does not recover Erk1/2 phosphorylation, restoring Ras activity by an active RasV12 fully rescues Erk1/2 activity and cell proliferation. Whether p140Cap controls Ras downstream to EGFR by affecting RasGAP activity remains to be investigated.
In conclusion, p140Cap controls EGFR signalling at least at two levels, the first one consisting in the inhibition of Src kinase activity resulting in E-cadherindependent EGFR inactivation at the cell membrane and impaired cell motility. As a second event, p140Cap can also directly affect Ras activation, thereby regulating cell proliferation ( Figure 7E ). Moreover, p140Cap is lost in 70% of human mammary carcinomas, including the most aggressive ones. Therefore, mechanistically, p140Cap operates as an oncosuppressor, maintaining cancer cells in a less aggressive phenotype.
Materials and methods

Reagents and antibodies See Supplementary information.
Cell lines, vectors and transfection MCF7 cells overexpressing p140Cap (p140-oe), silenced for p140Cap (p140-si) and the respective controls (Ctr and Ctr-si), were previously described (Di Stefano et al., 2007) . HT-29, obtained from ATCC, silenced for p140Cap were obtained by infecting exponentially growing HT-29 (1 Â 10 5 /ml) with pSuperRetro-p140-2 (Di Stefano et al., 2007) , in the presence of 8 microgram/ml polybrene (Sigma-Aldrich, St Louise, MO, USA) and selected with 1microgram/ml puromycin.
For immunofluorescence experiments, p140Cap-RFP constructs were obtained by digesting pEGFP-N1-p140Cap (Di Stefano et al., 2004) with HindIII-SalI restriction enzymes and cloning the fragment in pRFP-N1 (Clontech) digested with the same enzymes. EGFR-ECFP, E-Cadherin-GFP and pBabeRasV12 were kind gifts from A. Sorkin (Sorkin et al., 2000) , Jennifer Stow (Miranda et al., 2001 ) and PP Pandolfi. All these constructs were transiently transfected in MCF7 cells using FUGENE HD (Roche, Basilea, Switzerland).
Expression of the Csk kinase-defective mutant (CskKD) and Csk silencing were obtained as previously described (Di Stefano et al., 2007) .
Cell proliferation and cell scatter For cell proliferation, 10 4 cells were seeded on 6 tissue culture dishes and left to proliferate for 10 days in the presence of medium supplemented with 10% FCS. Every 2 days, cells were detached and manually counted in Burker chambers on triplicate wells. For specific experiments, 10 3 HT-29 cells or 5*10 3 MCF7 cells were plated on 96 multi-wells, and every 24 h cell growth was evaluated by MTT assay (Roche, Basilea, Switzerland) according to the manufacturer's instructions.
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For cell scatter, 1.5 Â 10 4 cells were plated in 24-well plates and allowed to form colonies, serum deprived for 12 h, incubated with EGF (50 ng/ml) in serum-free medium for 12 h and stained using the Diff-Quick kit (Dade Behering Deerfield, IL, USA). Colonies of 5-10 cells were photographed with a 20 Â objective and their area was measured with the Metamorph software.
EGF treatment, DECMA and Fc-E-cadherin assays One day before the assays in confluent conditions, cells were plated at confluence, serum deprived for 12 h and then incubated with EGF (30 ng/ml) in serum-free medium for 5 min. For experiments in sparse conditions, cells were plated as single cells in the presence of RPMI 10% FBS for 4 h and serum deprived for 12 h. Cells were then stimulated with EGF as described above.
For DECMA treatment, cells plated at 80-90% of confluence and serum deprived for 12 h were treated with EGTA 5 mM for 30 min and then incubated with DECMA mAb (10 microgram/ml) for 30 min. Where indicated, cells were treated with EGF as described above.
For the Fc-E-cadherin assay, cells were plated in sparse conditions as described above, serum deprived for 12 h, incubated at 37 1C with 2 microgram/ml of the human Fc-E-cadherin chimeric protein for 3 h and then stimulated with EGF.
Western blot and cell surface biotinylation Western blots were performed according to (Di Stefano et al., 2007) .
For biotinylation, cells were washed with Buffer A (1.3 mM CaCl2, 0.4 m, MgSO4, 5 mM KCl, 138 mM NaCl, 5,6 mM D-Glucose, 25 mM Hepes pH 7.4), incubated with 0.5 mg/ml Sulfo-NHS-Biotin in buffer A for 15 min and washed twice with buffer A. Biotinylation was repeated once and stopped by washing with RPMI-BSA 0,6%. Cell extracts were immunoprecipitated with E-cadherin mAb and biotinylated proteins were detected by incubation with streptavidin HRP.
Immunofluorescence and Fluorescence Recovery after photobleaching (FRAP) For EGTA treatment, cells plated onto glass coverslips in the presence of 10% FBS for 24 h were treated with 5 mM EGTA for 15 or 30 min, fixed and stained as described in Di Stefano et al., 2004. For colocalization experiments, MCF7 cells were transiently transfected with p140Cap-RFP and EGFR-ECFP, plated on glass coverslips for 24 h, processed as above and analysed with an Olympus FV1000 confocal microscope.
For FRAP experiments, 1.5 Â 10 6 cells were transfected with E-Cadherin-GFP and plated onto glass-bottomed 30 mm tissue culture dishes (Iwaki Cell Biology, Sterilin Ltd, Caerphilly, United Kingdom) and left to grow for 48 h. Culture media was replaced before imaging. Photo-bleaching experiments were performed using an Olympus FV1000 confocal microscope with SIM scanner, at 37 1C, in a temperature-controlled chamber using the following settings: pixel dwell time 4 microsec/px, pixel resolution 512 Â 512, 5% 488 nm laser power. Effective photo-bleaching was achieved using 50% 405 nm laser power, 20 microsec/pixel dwell time, and a 1 frame bleach time. Images were captured every 10 s for 120 frames. Up to 40 cells were imaged for each probe.
